As more people live longer, doctors are seeing an increase in the number of people with age-related eye problems.

In early research, OCU410ST, a gene therapy for Stargardt disease, demonstrated slowed lesion growth by 48% at the 12-month follow-up in evaluable treated eyes.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

Researchers demonstrated that systemic factors from young mice can rejuvenate the aging retina by alleviating cellular senescence and restoring function.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical firm pioneering therapies delivered through the suprachoroidal ...

Lawrence Sincich, Ph.D. Lawrence Sincich, Ph.D., professor at the University of Alabama at Birmingham School of Optometry was ...

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, ...

Our eyes are incredible tools, but like the rest of our bodies, they undergo changes as we age. Protecting your vision isn't ...

Hugh Linehan shares his experience of macular degeneration – and the losses, large and small, that come with it ...